Immediate Impact

1 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Fibroblasts in cancer: Unity in heterogeneity
2023 Standout
Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy
2022 Standout
2 intermediate papers

Works of Robert Grimshaw being referenced

A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: A National Cancer Institute of Canada Clinical Trials Group Study
2006
Randomized Trial of Two Intravenous Schedules of the Topoisomerase I Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials Group
2005

Author Peers

Author Last Decade Papers Cites
Robert Grimshaw 409 148 208 297 243 22 848
Peter Bryson 346 166 310 249 215 24 803
Sadako Nishimura 278 176 165 230 306 26 829
Susan Zweizig 412 152 179 187 372 31 884
J. Herod 269 271 172 378 261 23 894
Teresa Rutledge 300 100 158 271 308 37 897
Xi Cheng 342 138 267 254 252 30 882
N. Einhorn 551 94 311 197 279 35 951
Ate GJ van der Zee 232 145 177 184 388 13 775
Mark K. Dodson 278 94 175 180 302 42 854
Roberta Tana 324 186 204 181 385 22 780

All Works

Loading papers...

Rankless by CCL
2026